Management of hepatitis C virus infection in the setting of liver transplantation

Hector Rodriguez-Luna, Hugo E Vargas

Research output: Contribution to journalArticle

41 Citations (Scopus)

Abstract

HCV-related cirrhosis is still a valid indication for LT, despite the frequency of recurrence. As this segment of the LT-recipient population grows, the transplantation hepatologist needs to consider the challenge of preventing aggressive recurrence and considering the value of retransplantation in this patient group. Current treatment options for HCV offer limited chance of long-term success. There is ample room for investigation into the most beneficial regimen and duration of treatment, the time at which one should start, and how all the factors over which the clinician and patient have control will be manipulated to achieve the highest possible disease- and symptom-free survival.

Original languageEnglish (US)
Pages (from-to)479-489
Number of pages11
JournalLiver Transplantation
Volume11
Issue number5
DOIs
StatePublished - May 2005

Fingerprint

Virus Diseases
Hepacivirus
Liver Transplantation
Recurrence
Disease-Free Survival
Fibrosis
Transplantation
Therapeutics
Population
Gastroenterologists

ASJC Scopus subject areas

  • Surgery
  • Transplantation

Cite this

Management of hepatitis C virus infection in the setting of liver transplantation. / Rodriguez-Luna, Hector; Vargas, Hugo E.

In: Liver Transplantation, Vol. 11, No. 5, 05.2005, p. 479-489.

Research output: Contribution to journalArticle

@article{d000b37349d84f4f8e489689b2fcd19b,
title = "Management of hepatitis C virus infection in the setting of liver transplantation",
abstract = "HCV-related cirrhosis is still a valid indication for LT, despite the frequency of recurrence. As this segment of the LT-recipient population grows, the transplantation hepatologist needs to consider the challenge of preventing aggressive recurrence and considering the value of retransplantation in this patient group. Current treatment options for HCV offer limited chance of long-term success. There is ample room for investigation into the most beneficial regimen and duration of treatment, the time at which one should start, and how all the factors over which the clinician and patient have control will be manipulated to achieve the highest possible disease- and symptom-free survival.",
author = "Hector Rodriguez-Luna and Vargas, {Hugo E}",
year = "2005",
month = "5",
doi = "10.1002/lt.20424",
language = "English (US)",
volume = "11",
pages = "479--489",
journal = "Liver Transplantation",
issn = "1527-6465",
publisher = "John Wiley and Sons Ltd",
number = "5",

}

TY - JOUR

T1 - Management of hepatitis C virus infection in the setting of liver transplantation

AU - Rodriguez-Luna, Hector

AU - Vargas, Hugo E

PY - 2005/5

Y1 - 2005/5

N2 - HCV-related cirrhosis is still a valid indication for LT, despite the frequency of recurrence. As this segment of the LT-recipient population grows, the transplantation hepatologist needs to consider the challenge of preventing aggressive recurrence and considering the value of retransplantation in this patient group. Current treatment options for HCV offer limited chance of long-term success. There is ample room for investigation into the most beneficial regimen and duration of treatment, the time at which one should start, and how all the factors over which the clinician and patient have control will be manipulated to achieve the highest possible disease- and symptom-free survival.

AB - HCV-related cirrhosis is still a valid indication for LT, despite the frequency of recurrence. As this segment of the LT-recipient population grows, the transplantation hepatologist needs to consider the challenge of preventing aggressive recurrence and considering the value of retransplantation in this patient group. Current treatment options for HCV offer limited chance of long-term success. There is ample room for investigation into the most beneficial regimen and duration of treatment, the time at which one should start, and how all the factors over which the clinician and patient have control will be manipulated to achieve the highest possible disease- and symptom-free survival.

UR - http://www.scopus.com/inward/record.url?scp=18944393455&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=18944393455&partnerID=8YFLogxK

U2 - 10.1002/lt.20424

DO - 10.1002/lt.20424

M3 - Article

C2 - 15838917

AN - SCOPUS:18944393455

VL - 11

SP - 479

EP - 489

JO - Liver Transplantation

JF - Liver Transplantation

SN - 1527-6465

IS - 5

ER -